ENTITY
Shenzhen Hepalink Pharmaceutical

Shenzhen Hepalink Pharmaceutical (9989 HK)

97
Analysis
Health Care • China
Shenzhen Hepalink Pharmaceutical is a multinational biopharmaceutical company with core businesses in the heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. Its key products include heparin sodium APIs and enoxaparin sodium preparations. The company is headquartered in Shenzhen, China, and was founded in 1998.
more
•03 Dec 2023 10:10

A-H Premium Weekly (Dec 1st): CMB, Ping An Insurance, Beigene, Ganfeng Lithium

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CMB, Ping An Insurance, Beigene, Ganfeng Lithium.

Logo
727 Views
Share
•26 Nov 2023 10:10

A-H Premium Weekly (Nov 24th): Angang Steel, Gwmotor, YOFC, Sinopec Oilfield

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Angang Steel, Gwmotor, YOFC, Sinopec Oilfield.

Logo
584 Views
Share
•19 Nov 2023 10:10

A-H Premium Weekly (Nov 17th): Ganfeng Lithium, BYD, CICC, Shanghai Fudan, Huahong

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Ganfeng Lithium, Byd Company, CICC, Shanghai Fudan, Huahong.

Logo
668 Views
Share
•12 Nov 2023 10:10

A-H Premium Weekly (Nov 10th): Ping An Insurance, Ganfeng Lithium, GWM, China Longyuan

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Ping An Insurance, Ganfeng Lithium, Gwmotor, China Longyuan.

Logo
578 Views
Share
•05 Nov 2023 10:10

A-H Premium Weekly (Nov 3rd): Ganfeng Lithium, CMS, Wuxi Apptec

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Ganfeng Lithium, China Merchant Securities and Wuapptec.

Logo
613 Views
Share
x